We characterized differences in the natural history of patients with EGFR-mutated NSCLC whose tumors develop a T790M resistance mutation compared with those whose tumors do not. We found T790M D patients had a longer PFS with first-line TKI and chemotherapy, but no difference with TKI rechallenge. Response rate was similar for all therapies evaluated, even when differences in PFS were seen. Background: The secondary T790M mutation accounts for more than 50% of acquired tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutated nonesmall-cell lung cancer (NSCLC). Recent reports suggest this resistance mutation may be more common among patients with longer progression-free survival (PFS) on first-line TKI therapy, but much is still unknown. Materials and Methods: Our group collected medical records from patients who underwent a biopsy for T790M mutation testing while screening for clinical trials involving the drug rociletinib (CO-1686), a T790M mutationespecific TKI. Medical records were retrospectively analyzed for demographic data, PFS, and best response to previous therapies. Results: Our patient cohort included 69 T790M þ patients and 28 T790M À patients. Patients who later developed a T790M mutation had a longer PFS on first-line TKI therapy (12.0 vs. 9.0 months, P ¼ .021), but overall response rate (ORR) was the same (75.0% vs. 81.0%, P ¼ .76). There was no difference in PFS on TKI rechallenge (4.0 vs. 3.0 months, P ¼ .94), although there was a trend toward higher ORR in T790M þ patients (22.2% vs. 0%, P ¼ .12). T790M þ patients had a longer PFS on initial chemotherapy treatment (5.0 vs. 4.0 months, P ¼ .025) and a trend toward higher ORR (40.0% vs. 21.4%, P ¼ .31). Conclusion: Our study confirms that tumors expressing T790M have a more indolent progression of disease compared with their T790M À counterparts when treated with both first-line TKI and cytotoxic chemotherapy.
Introduction
Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase have emerged as an important treatment target for nonesmall-cell lung cancer (NSCLC), a disease for which the current 5-year survival rate for patients with stage IV is only 1%. 1 This molecular subtype of EGFR mutations is present in up to half of patients with NSCLC in Asian populations 2 and approximately 10%
in Western populations. [3] [4] [5] It is also known to be more common in women, never-smokers, and those with adenocarcinoma histology. 2, 6 First-generation tyrosine kinase inhibitors (TKIs) against EGFR, including erlotinib and gefitinib, have been shown to be superior to chemotherapy as first-line treatment for patients with EGFRmutated NSCLC, leading to longer progression-free survival (PFS). [7] [8] [9] [10] [11] [12] [13] [14] Overall survival (OS), however, has not been shown to be statistically different between first-generation TKIs and chemotherapy, possibly due to crossover at disease progression. 7, 8, 10, 11, 13, 14 Of the 2 most common types of EGFR mutations, patients with the exon 19 deletion have recently been suggested to have a longer PFS on TKIs and also a longer OS than those with the L858R point mutation, 6, 15, 16 although data have been somewhat conflicting. 17, 18 Despite the initial beneficial response to TKIs, most patients with NSCLC with EGFR-activating mutations develop resistance, generally 9 to 14 months after treatment initiation. [6] [7] [8] [9] 12, 19, 20 Although multiple mechanisms have been described, a secondary EGFR mutation Thr790Met (T790M) in exon 20 accounts for more than 50% of acquired TKI resistance. [21] [22] [23] Second-generation TKIs, including afatinib and dacomitinib, were developed to combat such acquired resistance, but limited efficacy has been observed. [24] [25] [26] [27] More recently, third-generation drugs, including rociletinib and osimertinib, have been designed to irreversibly inhibit the tyrosine kinase activity of mutant EGFR, including both activating and the T790M resistance mutations, without affecting wild-type EGFR. 28, 29 Investigation into acquired resistance due to the T790M mutation is ongoing, but much is still unknown. Some studies have shown that patients who are T790M-positive (T790M þ ) have a longer PFS on erlotinib treatment, 23 a longer post-progression survival (PPS) following progression on TKI treatment, 30, 31 and a longer OS compared with patients who are T790M-negative (T790M À   ) , 23, 30, 32, 33 suggesting that those patients who develop a T790M mutation may have a more favorable prognosis and a more indolent progression of disease than those who develop another resistance mechanism to TKIs. Our study aimed to examine patients harboring a T790M mutation in terms of their response to treatment, including not only EGFR-TKIs but also chemotherapy, to help further characterize this important subset of patients.
Materials and Methods

Patients and Study Design
The patient cohort for this study was acquired from enrolled and screen-failed patients for the clinical trials NCT02147990 (TIGER-2) and NCT01526928 (TIGER-X) 34, 35 involving the thirdgeneration TKI rociletinib (CO-1686), an irreversible inhibitor of the T790M resistance mutation, as well as the exon 19 and 21 mutations commonly present in EGFR-mutated NSCLC. 29, 36 Inclusion criteria for these studies included histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC, life expectancy of at least 3 months, Eastern Cooperative Oncology Group performance status of 0 to 1, adequate hematological and biological function as confirmed by laboratory values, and documented evidence of an activating mutation in EGFR, in addition to undergoing a biopsy of either primary or metastatic tumor tissue within 28 days (TIGER-2) or 60 days (TIGER-X) of starting the study drug. Patients were also required to have disease progression on treatment with a prior EGFR-directed therapy (eg, erlotinib, gefitinib, neratinib, afatinib, or dacomitinib) and have documented evidence of a T790M mutation in EGFR following disease progression on most recent prior EGFR-directed therapy, with the exception of phase 1 of TIGER-X for which T790M mutation testing was not required. T790M mutation testing was performed by polymerase chain reactionebased testing of tumor tissue using the University of California, Los Angeles, central laboratory. Medical records were retrospectively analyzed for demographic data, PFS, best response (BR) to previous therapies, and T790M mutation status. No analysis was done on clinical trial data. Analysis was performed only on therapies given before the study drug, with the exception of chemotherapy, for which 5 patients received initial chemotherapy after study drug. As most of the therapies were not on a clinical trial and often administered at outside institutions, the date of progression was defined based on either (1) radiographic progression based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumours) 37 or (2) 
Statistical Analysis
The associations between T790M and patient demographics/ clinical characteristics were analyzed using the 2-sample t test and c 2 test. PFS was estimated using the Kaplan-Meier method and compared across 2 groups using the log-ranked test. Univariable and multivariable analyses were performed using Cox proportional hazard regression analysis. In multivariable analysis, all variables with P < .2 by univariable analysis were added into the basic model, which included the study variable of T790M mutation status. A final model was obtained first by backward elimination and then verified by the stepwise model selection method, retaining the study variable of T790M mutation status. Results were considered statistically significant if P < .05.
Results
Patient Population
From April 2012 to October 2016, 125 patients were screened at our institution for clinical trials involving the third-generation TKI rociletinib ( Figure 1 ). Nineteen patients were excluded from our study because of unknown T790M status due to (1) a nondiagnostic biopsy, (2) biopsy not being obtained at our institution as a result of poor performance status or transfer of care, or (3) biopsy not being required for clinical trial screening given patient was being screened for phase 1 of TIGER-X. Of the 106 patients who received a diagnostic biopsy identifying the presence or absence of a T790M mutation, 8 patients (6 T790M þ and 2 T790M À ) were excluded because they were treated with erlotinib and/or chemotherapy in the adjuvant setting after definitive surgery or radiation with no evidence of disease, and the PFS and response rate endpoints in this adjuvant setting were not considered comparable to that in the metastatic setting. One T790M À patient was also excluded because the patient possessed an EGFR mutation known to be e20 -Clinical Lung Cancer January 2018
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nonsensitizing to approved EGFR-TKIs (exon 20 insertion). Ninety-seven patients had advanced disease (stage IV) at the time of TKI or chemotherapy treatment that was either advanced at diagnosis or recurrent from stage I, II, or III disease at diagnosis. Of those 97 patients, 69 had a biopsy positive for the T790M mutation and 28 were found to be T790M À .
Characteristics of the 97 patients are outlined in Table 1 . In both T790M
þ and T790M À patients, most were women and neversmokers, and the exon 19 deletion was the most common EGFRactivating mutation. Seven patients (4 T790M
unknown EGFR mutational status for primary EGFR mutation given incomplete documentation. Although the distinction between exon 19 deletion and L858R was not made, it was documented for these 7 patients that primary EGFR mutations were sensitizing and/or appropriate for erlotinib therapy. Almost all patients had advanced stage IV disease at diagnosis, but a small number had recurrent disease after definitive therapy, such as surgery, chemotherapy, radiation, or TKI treatment. There was no difference in clinical characteristics of patients based on T790M mutation status. 
PFS and Tumor Response to First TKI Treatment
Analysis of first-line TKI treatment was performed for 66 T790M þ patients and 28 T790M À patients. Three T790M þ patients were excluded from analysis because they received TKI therapy before progression to stage IV disease (but received chemotherapy once disease was metastatic, so were not excluded (Figure 3 ; P ¼
.014 by log-rank test). Univariable analysis showed an association with shorter PFS on chemotherapy with the absence of a T790M mutation ( to T790M mutation status, our results showed an association for a shorter PFS on first-line TKI treatment with male sex (P ¼ .010) and a positive smoking history (P ¼ .011), as has been shown in other studies. 6, 41, 42 We did not find the same positive association with exon 19 deletion compared with L858R that had been documented in some reports. 6, 15 Results were also unchanged if patients who received TKI in combination with other agents were removed from the analysis, which is in line with current data that there has not yet been a proven benefit for combination use of TKI with other agents. [43] [44] [45] There has been an improved PFS noted for first-line this is the first study to report on differences in PFS and response to chemotherapy based on T790M mutation status. Although OS was not assessed in this analysis given selective follow-up of patients enrolled in the clinical trials with T790M positivity (and lack of data on screen-failed T790M À patients), other reports have indicated a longer PPS 30, 31 and a longer OS for T790M þ patients. 23, 30, 32, 33, 38 Our study, as well as the others documented previously, therefore demonstrate that patients with and without the T790M mutation [49] [50] [51] It has also been shown that stopping TKI therapy in patients who develop acquired resistance can result in progression 52 and even rapid worsening of symptoms or "disease flare" due to regrowth of TKI-sensitive clones, 53 although no association was noted between such disease flare and T790M positivity at time of progression. 53 However, data are not yet conclusive at this point, as evidenced by the Soria et al 45 IMPRESS study, which demonstrated that continuing TKI therapy beyond progression is not of benefit. T790M subgroup analysis from this study actually showed that continued TKI maintenance during chemotherapy was more beneficial for T790M À than T790M þ patients. 54 Further studies should be performed to further evaluate TKI continuation beyond progression, specifically in relation to T790M mutation status. Third-generation TKIs have been developed to specifically inhibit the T790M mutation. On the basis of clinical efficacy demonstrated in the AURA and AURA2 trials, 55, 56 osimertinib was granted approval by the Food and Drug Administration in November 2015 for treatment of patients whose tumors harbor EGFR T790M and whose disease worsened after treatment with other EGFR-inhibiting therapies. 57 The most recently published AURA3 study showed increased efficacy for osimertinib compared with chemotherapy in T790M þ EGFR-mutant patients who had progressed on first-line EGFR TKI therapy. 58 Although data were also initially promising for rociletinib based on the original publication from the phase 1/2 studies, 34 the updated confirmed response rates 35 led to termination of drug development.
We found that patients who received chemotherapy before TKI had a trend toward a longer PFS compared with those who received chemotherapy after TKI (P ¼ .019). This is consistent with Zeng et al 59 who demonstrated that frontline EGFR TKI treatment significantly reduced the PFS and response rate of subsequent chemotherapy in comparison with TKI-naïve patients who received frontline chemotherapy. Importantly, the response rate and PFS of TKI treatment were similar in chemotherapy-naïve and -refractory patients, suggesting that TKI treatment after chemotherapy would not reduce its efficacy. 6, 59 Our study actually demonstrated a numerically improved PFS on TKI if TKI was given after chemotherapy (P ¼ .0070). OS has likewise been shown to be longer for patients receiving frontline versus post-TKI chemotherapy. 59, 60 In line with this data, several preclinical studies have suggested that EGFR TKI and chemotherapy may influence the efficacy of each other. 61, 62 And, although there is generous evidence that TKIs are superior to chemotherapy for PFS when both are given as first-line treatment, an OS benefit for first-line TKI over first-line chemotherapy has never been demonstrated, though this has been attributed to crossover at disease progression. [7] [8] [9] [10] [11] [12] [13] [14] In T790M þ patients in particular, the third-line TKI osimertinib has been shown to be more efficacious than chemotherapy after progression on first-line TKI therapy. 58 As all of these studies, including ours, are retrospective, a prospective trial is needed to evaluate the extent of interaction between TKI and chemotherapy, as there may be a benefit to first-line chemotherapy in patients with EGFR-mutated NSCLC. Our study includes several limitations. First, our data set is of limited size and the data are retrospective. There was also a predominance of T790M þ patients compared with T790M À patients, likely due to referral bias (some patients were sent for clinical trial screening after already obtaining a biopsy positive for T790M at an outside institution). Second, our sample included only patients who were able to undergo a diagnostic biopsy. Although the excluded patients were mostly those whose biopsy did not obtain an adequate tissue sample or those who did not need a biopsy to enroll in the clinical trial, there were also patients who never underwent biopsy due to poor performance status and were presumably sicker individuals with a poorer overall prognosis that could have affected our analysis. Third, there are limitations to our measurements of PFS and response rate, as radiological scans were not available for all patients, given they were treated as standard of care and not a clinical trial protocol and also at outside institutions. Last, our study does not differentiate based on other possible mechanisms of resistance to EGFR TKI treatment, such as MET amplification, HER2 amplification, BRAF mutations, PIK3CA mutations, epithelial-to-mesenchymal transition, or small cell transformation, 43, 63 and the non-T790M patients most likely are not a homogeneous group.
Conclusion
In conclusion, our study validates that tumors expressing the T790M resistance mutation have a more indolent progression of disease than their T790M À counterparts as evidenced by a longer PFS on first-line TKI and chemotherapy, although no difference in PFS was noted for TKI rechallenge. Improved knowledge of the molecular mechanisms of T790M þ and T790M À forms of resistance is necessary to develop and further evaluate new therapeutic strategies.
Clinical Practice Points
The clinical efficacy of EGFR-TKIs in EGFR-mutated NSCLC is limited by the development of drug resistance mutations, most commonly the T790M resistance mutation. The present study aimed to further characterize patients harboring a T790M mutation in terms of their response to various treatments, including EGFR-TKIs (first-line and rechallenge) and chemotherapy. In our cohort, T790M þ patients were found to have a longer PFS on first-line TKI (P ¼ .021), but there was no difference in response rate based on T790M mutation status (P ¼ .76). There was no difference in PFS on TKI rechallenge based on T790M mutation status (P ¼ .94), although there was a trend toward higher response rate in T790M þ patients (P ¼ .12).
T790M
þ patients also had a longer PFS on chemotherapy (P ¼
.025) and a trend toward higher response rate compared with their T790M À counterparts (P ¼ .31).
T790M Mutation in EGFR-Mutated NSCLC
e26 -Clinical Lung Cancer January 2018
Our study confirms that T790M þ patients have a more indolent progression of disease compared with T790M À patients.
